Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma.
Level 5 - mechanism / opinion, no new human data
Animal model study with no human data.
PubMed 22422004 · doi:10.1038/embor.2012.32
What was done
Neonatal mice were treated with clinical doses of two antibiotics, streptomycin and vancomycin, to evaluate changes in resident gut microbiota and subsequent susceptibility to experimental allergic asthma. The same antibiotic treatments were also administered to adult mice to assess age-dependent susceptibility.
What was found
The abstract reports no numerical data. Streptomycin treatment had little effect on the microbiota and on disease outcomes. Vancomycin treatment in neonatal mice reduced microbial diversity, altered bacterial population composition, and enhanced asthma disease severity. Neither antibiotic had a significant effect on microbiota or disease when administered to adult mice.
Why it matters
This study provides experimental support in an animal model for the hygiene hypothesis, identifying an early-life window where antibiotic-driven gut microbiota disruption increases susceptibility to allergic airway disease.
Limits
The study was conducted entirely in mice, limiting direct translation to human asthma. The abstract does not report sample sizes, specific bacterial taxa, quantitative effect sizes, or immunological parameters measured.
Cited by
- supports Early life exposure to antibiotics in mice and humans increases the risk of developing asthma and obesity later in life.